T1	PROC 46 62	Estudio fase IIB
T2	CHEM 69 78	nivolumab
#1	AnnotatorNotes T2	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 107 133	linfoma de Hodgkin clásico
#2	AnnotatorNotes T3	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T4	PROC 163 214	trasplante autólogo de progenitores hematopoyéticos
T5	PROC 244 322	Estudio fase II no comparativo, de múltiples cohortes, de brazo único, abierto
T6	CHEM 338 348	BMS-936558
#3	AnnotatorNotes T6	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	CHEM 327 336	nivolumab
#4	AnnotatorNotes T7	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	DISO 365 391	linfoma de Hodgkin clásico
#5	AnnotatorNotes T8	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
T9	PROC 421 472	trasplante autólogo de progenitores hematopoyéticos
T10	DISO 503 524	Enfermedad de Hodgkin
#6	AnnotatorNotes T10	C0019829; Hodgkin Disease; Neoplastic Process
T11	DISO 552 573	Enfermedad de Hodgkin
#7	AnnotatorNotes T11	C0019829; Hodgkin Disease; Neoplastic Process
T12	PROC 660 701	quimioterapia previa de acondicionamiento
T13	PROC 747 769	tratamiento de rescate
#8	AnnotatorNotes T13	C0085405; Salvage Therapy; Therapeutic or Preventive Procedure
T14	PROC 814 825	tratamiento
#9	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	PROC 874 885	tratamiento
#10	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 947 954	Linfoma
#11	AnnotatorNotes T16	C0024299; Lymphoma; Neoplastic Process
T17	ANAT 968 992	sistema nervioso central
#12	AnnotatorNotes T17	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T18	DISO 1007 1043	LH nodular de predominio linfocítico
#13	AnnotatorNotes T18	C1334968; Hodgkin lymphoma, nodular lymphocyte predominance; Neoplastic Process
T19	ANAT 1032 1043	linfocítico
#14	AnnotatorNotes T19	C0024264; Lymphocyte; Cell
T20	ANAT 1070 1078	torácica
#15	AnnotatorNotes T20	C0817096; Chest; Body Location or Region | C1269614; Entire thorax; Body Part, Organ, or Organ Component
T21	CHEM 1122 1133	medicamento
#16	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	PROC 1060 1078	Radiación torácica
T23	CHEM 1148 1158	Carmustina
#17	AnnotatorNotes T23	C0007257; carmustine; Organic Chemical · Pharmacologic Substance
T24	CHEM 1160 1164	BCNU
#18	AnnotatorNotes T24	C0007257; carmustine; Organic Chemical · Pharmacologic Substance
T25	PROC 1204 1232	régimen de acondicionamiento
#19	AnnotatorNotes T25	C0376450; Transplantation Conditioning; Therapeutic or Preventive Procedure
T26	PROC 216 220	TAPH
#20	AnnotatorNotes T26	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
T27	ANAT 186 214	progenitores hematopoyéticos
#21	AnnotatorNotes T27	C0018956; Hematopoietic stem cells; Cell
T28	DISO 393 396	LHc
T29	ANAT 444 472	progenitores hematopoyéticos
#22	AnnotatorNotes T29	C0018956; Hematopoietic stem cells; Cell
T30	DISO 775 778	LHc
T31	PROC 1046 1050	TAPH
#23	AnnotatorNotes T31	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
T32	CHEM 80 90	BMS-936558
#24	AnnotatorNotes T32	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	DISO 135 138	LHc
T34	PROC 474 478	TAPH
#25	AnnotatorNotes T34	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
T35	PROC 728 732	TAPH
#26	AnnotatorNotes T35	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
T36	DISO 152 214	fracaso de trasplante autólogo de progenitores hematopoyéticos
T37	DISO 410 472	fracaso de trasplante autólogo de progenitores hematopoyéticos
T38	CHEM 830 849	brentuximab vedotin
#27	AnnotatorNotes T38	C2973446; brentuximab vedotin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T39	CHEM 897 916	brentuximab vedotin
#28	AnnotatorNotes T39	C2973446; brentuximab vedotin; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	Date 13 17	2014
T41	LIVB 95 102	sujetos
#29	AnnotatorNotes T41	C0681850; Study Subject; Group
T43	LIVB 289 297	cohortes
#30	AnnotatorNotes T43	C0599755; Cohort; Population Group
T44	LIVB 353 360	sujetos
#31	AnnotatorNotes T44	C0681850; Study Subject; Group
T47	Dose 704 715	dosis altas
#32	AnnotatorNotes T47	C0444956; High dose; Quantitative Concept
T48	LIVB 786 793	sujetos
#33	AnnotatorNotes T48	C0681850; Study Subject; Group
T49	Neg_cue 805 813	naive al
T51	LIVB 995 1002	Sujetos
#34	AnnotatorNotes T51	C0681850; Study Subject; Group
T52	Duration 1079 1091	≤ 24 semanas
T53	CONC 1104 1117	primera dosis
T54	Dose 1166 1177	≥ 600 mg/m²
T56	PHYS 199 214	hematopoyéticos
#35	AnnotatorNotes T56	C0018951; Hematopoiesis; Organ or Tissue Function
T58	PHYS 457 472	hematopoyéticos
#36	AnnotatorNotes T58	C0018951; Hematopoiesis; Organ or Tissue Function
T59	Date 1233 1246	pretrasplante
T42	PROC 602 618	Estado funcional
#38	AnnotatorNotes T42	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
A3	Status T14 History_of
A4	Assertion T14 Negated
A5	Status T38 History_of
A6	Assertion T38 Negated
A7	Status T15 History_of
A8	Status T39 History_of
A9	Status T31 History_of
A10	Status T12 History_of
A11	Status T35 History_of
A12	Status T13 History_of
A1	Status T34 History_of
A2	Status T9 History_of
A13	Status T4 History_of
A14	Status T26 History_of
A15	Status T16 History_of
#39	AnnotatorNotes T1	C1706096; Phase II B Trial; Research Activity 
#40	AnnotatorNotes T33	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
#41	AnnotatorNotes T28	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
#42	AnnotatorNotes T30	C1333064; Classical Hodgkin's Lymphoma; Neoplastic Process
#43	AnnotatorNotes T4	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
#44	AnnotatorNotes T9	C2193200; Autologous hematopoietic stem cell transplant; Therapeutic or Preventive Procedure
T45	Neg_cue 260 262	no
T46	Quantifier_or_Qualifier 263 274	comparativo
A16	Assertion T46 Negated
R1	Negation Arg1:T45 Arg2:T46	
R2	Experiences Arg1:T41 Arg2:T2	
R3	Experiences Arg1:T41 Arg2:T32	
R4	Experiences Arg1:T41 Arg2:T3	
R5	Experiences Arg1:T41 Arg2:T33	
R6	After Arg1:T2 Arg2:T36	
R7	After Arg1:T32 Arg2:T36	
R8	Experiences Arg1:T41 Arg2:T36	
R9	Experiences Arg1:T41 Arg2:T4	
R10	Experiences Arg1:T41 Arg2:T56	
R12	Before Arg1:T4 Arg2:T36	
R15	Before Arg1:T26 Arg2:T36	
R18	Experiences Arg1:T43 Arg2:T7	
R19	Experiences Arg1:T43 Arg2:T6	
R20	Experiences Arg1:T43 Arg2:T8	
R21	Experiences Arg1:T43 Arg2:T28	
R22	Experiences Arg1:T43 Arg2:T37	
R23	Experiences Arg1:T43 Arg2:T9	
R24	Experiences Arg1:T43 Arg2:T58	
R25	Experiences Arg1:T43 Arg2:T34	
R26	Experiences Arg1:T44 Arg2:T7	
R27	Experiences Arg1:T44 Arg2:T6	
R28	Experiences Arg1:T44 Arg2:T8	
R29	Experiences Arg1:T44 Arg2:T28	
R30	Experiences Arg1:T44 Arg2:T37	
R31	Experiences Arg1:T44 Arg2:T58	
R32	Experiences Arg1:T44 Arg2:T34	
R35	Before Arg1:T9 Arg2:T37	
R36	Before Arg1:T34 Arg2:T37	
R39	After Arg1:T7 Arg2:T37	
R40	After Arg1:T6 Arg2:T37	
T50	CONC 619 623	ECOG
#37	AnnotatorNotes T50	C1520224; ECOG performance status; Intellectual Product
R43	Used_for Arg1:T50 Arg2:T42	
T55	Result_or_Value 627 632	0 ó 1
R44	Has_Result_or_Value Arg1:T50 Arg2:T55	
R45	Has_Dose_or_Strength Arg1:T12 Arg2:T47	
R46	Before Arg1:T12 Arg2:T35	
R47	Before Arg1:T12 Arg2:T13	
R48	Experiences Arg1:T48 Arg2:T14	
R49	Negation Arg1:T49 Arg2:T14	
R50	Negation Arg1:T49 Arg2:T38	
R51	Used_for Arg1:T38 Arg2:T14	
R52	Experiences Arg1:T48 Arg2:T15	
R53	Used_for Arg1:T39 Arg2:T15	
R54	Location_of Arg1:T17 Arg2:T16	
R55	Location_of Arg1:T19 Arg2:T18	
R56	Experiences Arg1:T51 Arg2:T18	
R57	Has_Duration_or_Interval Arg1:T22 Arg2:T52	
R58	Location_of Arg1:T20 Arg2:T22	
R59	Before Arg1:T22 Arg2:T21	
R60	Has_Dose_or_Strength Arg1:T21 Arg2:T53	
R61	Has_Dose_or_Strength Arg1:T24 Arg2:T54	
R62	Has_Dose_or_Strength Arg1:T23 Arg2:T54	
R63	Overlap Arg1:T25 Arg2:T59	
R64	Used_for Arg1:T24 Arg2:T25	
R65	Used_for Arg1:T23 Arg2:T25	
R11	Experiences Arg1:T41 Arg2:T26	
#45	AnnotatorNotes R60	(?)
#46	AnnotatorNotes T53	C5236155; Date of First Dose; Temporal Concept
#47	AnnotatorNotes T12	C5708002; Conditioning Chemotherapy; Therapeutic or Preventive Procedure
A17	Experiencer T44 Patient
A18	Experiencer T43 Patient
A19	Experiencer T41 Patient
A20	Experiencer T48 Patient
A21	Experiencer T51 Patient
